ClinicalTrials.gg
CompletedNCT01106014GRIPHONUpdated Oct 27, 2025Results posted

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

A Phase 3 interventional study of Selexipag and Placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 182 sites in 39 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2009, registered Apr 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,156
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
Largest of 12
1,156 · median 67
Started
2009
the only one that year
Phase 3
6 of 12
1 open now
Registered
1st of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one has the largest enrollment, is the only one that started in 2009, is one of 6 in phase 3, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • PAH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18-75 years old, with symptomatic PAH
  • PAH belonging to the following subgroups of the updated Dana Point Clinical Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or Associated (APAH) with Connective tissue disease, Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair, or infection)
  • Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at any time prior to Screening
  • Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior to the Baseline Visit
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Patients with pulmonary hypertension (PH) in the Updated Dana Point Classification Groups 2-5, and PAH Group 1 subgroups that are not covered by the inclusion criteria
  • Patients who have received prostacyclin or its analogs within 1 month before Baseline Visit, or are scheduled to receive any of these compounds during the trial
  • Patients with moderate or severe obstructive lung disease
  • Patients with moderate or severe restrictive lung disease
  • Patients with moderate or severe hepatic impairment ( B and C)
  • Patients with documented left ventricular dysfunction
  • Patients with severe renal insufficiency
  • Patients with \<18.5 Kg/m2
  • Patients who are receiving or have been receiving any drugs within 1 month before the Baseline Visit
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6MWT
  • Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training
  • Psychotic, addictive or other disorder limiting the ability to provide or to comply with study requirements
  • less than 12 months
  • Females who are lactating or pregnant or plan to become pregnant during the study
  • Known to any of the of the drug formulations
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,156 participants (actual)

Study arms

  • Experimental
    1

    Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose

    Drug: Selexipag

  • Placebo comparator
    2

    Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed

    Drug: Placebo

Interventions

  • Selexipag 200 µg tablets

    Also known as: ACT-293987

  • DrugPlacebo

    Placebo tablets matching selexipag

06

What researchers measure

Primary outcomes

  1. Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake

    Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points). Morbidity event was defined as any of the following events confirmed by the Critical Event committee: * Hospitalization for worsening of pulmonary arterial hypertension (PAH), * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy, * Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH, * Disease progression which was defined by a decrease in 6-minute walk distance from baseline (\>=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline. Note: The number of patients at risk decreased over time but this cannot be captured below

    Time frame: Up to 7 days after end of double-blind treatment (maximum: 4.3 years)

Secondary outcomes

  1. Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough

    The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.

    Time frame: Week 26

  2. Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)

    Time frame: Week 26

07

Results

Posted Mar 1, 2016

Participant flow

A total of 1351 patients were screened from 181 sites in 39 countries worldwide. Of these, 1156 were randomized

Participant flow — Overall Study
MilestoneSELEXIPAGPLACEBO
Started574582
Completed289252
Not completed285330
Withdrew: Morbidity or mortality primary endpoint155242
Withdrew: Adverse event7842
Withdrew: Withdrawal by subject4337
Withdrew: Administrative reason76
Withdrew: Lost to follow-up23

Outcome measures

PrimaryTime From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake

Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points). Morbidity event was defined as any of the following events confirmed by the Critical Event committee: * Hospitalization for worsening of pulmonary arterial hypertension (PAH), * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy, * Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH, * Disease progression which was defined by a decrease in 6-minute walk distance from baseline (\>=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline. Note: The number of patients at risk decreased over time but this cannot be captured below

Time frame:
Up to 7 days after end of double-blind treatment (maximum: 4.3 years)
Reported as:
Number · Percentage of patients free of events
Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake
Percentage of patients free of eventsSelexipagPlacebo
KM estimate at Month 691.2 (88.5 to 93.4)81.7 (78.2 to 84.7)
KM estimate at Month 1283.1 (79.5 to 86.1)70.6 (66.6 to 74.3)
KM estimate at Month 1875.5 (71.2 to 79.2)61.3 (56.8 to 65.5)
KM estimate at Month 2467.9 (63.0 to 72.4)53.9 (49.0 to 58.5)
KM estimate at Month 3061.9 (56.3 to 66.9)49.3 (44.2 to 54.3)
KM estimate at Month 3658.2 (51.7 to 64.1)41.7 (35.2 to 48.0)
Statistical analysis
  • Selexipag vs Placebo · Log Rank · p = <0.0001 (one-sided p-value) · Hazard ratio (hr): 0.6 · 99% CI 0.46 to 0.78
SecondaryChange From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough

The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.

Time frame:
Week 26
Reported as:
Median · Meters
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough
MetersSelexipagPlacebo
6MWD at baseline - Overall376 (90 to 482)369 (50 to 515)
6MWD at Week 26- Overall370 (0 to 617)346 (0 to 650)
6MWD Change from baseline at Week 264 (-448 to 260)-9 (-438 to 262)
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · p = 0.0027 (One-sided p-value of the nonparametric ANCOVA, adjusted for 6-minute walk distance at baseline) · Median difference (final values): 12 · 99% CI 1 to 24Point estimate and 2-sided 99% CI for location shift using the HodgesLehmann method
SecondaryAbsence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)
Time frame:
Week 26
Reported as:
Number · Percentage of patients
Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)
Percentage of patientsSelexipagPlacebo
Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)77.874.9
Statistical analysis
  • Selexipag vs Placebo · Cochran-Mantel-Haenszel · p = 0.2843 (Cochran-Mantel-Haenszel test stratified by WHO FC at baseline. For patients with missing NYHA/WHO FC at Week 26, the NYHA/WHO FC is considered as having worsened from baseline at Week 26. Missing values were imputed for 18.3% of subjects .) · Odds ratio, log: 1.161 · 99% CI 0.811 to 1.664

Adverse events

Collected over From baseline up to up to 7 days after end of treatment (EOT). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag—252/575 (43.8%)544/575 (94.6%)
Placebo—272/577 (47.1%)486/577 (84.2%)
Most frequent serious events
Showing 10 of 351
Most frequent serious events
EventSelexipagPlacebo
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders83/575127/577
RIGHT VENTRICULAR FAILURECardiac disorders34/57541/577
PNEUMONIAInfections and infestations17/57525/577
SYNCOPENervous system disorders10/57520/577
DYSPNOEARespiratory, thoracic and mediastinal disorders17/57513/577
ATRIAL FIBRILLATIONCardiac disorders7/5754/577
BRONCHITISInfections and infestations6/5754/577
CHEST PAINGeneral disorders6/5756/577
RENAL FAILURE ACUTERenal and urinary disorders6/5756/577
FALLInjury, poisoning and procedural complications3/5756/577
Most frequent other events
Showing 10 of 28
Most frequent other events
EventSelexipagPlacebo
HEADACHENervous system disorders374/575189/577
DIARRHOEAGastrointestinal disorders242/575109/577
NAUSEAGastrointestinal disorders192/575107/577
PAIN IN JAWMusculoskeletal and connective tissue disorders148/57536/577
DYSPNOEARespiratory, thoracic and mediastinal disorders79/575110/577
VOMITINGGastrointestinal disorders103/57548/577
OEDEMA PERIPHERALGeneral disorders77/575100/577
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders95/57546/577
MYALGIAMusculoskeletal and connective tissue disorders90/57534/577
DIZZINESSNervous system disorders85/57585/577

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SelexipagPlaceboTotal
Mean48.2 ± 15.1947.9 ± 15.5548.1 ± 15.37
Sex: Female, Male
Sex: Female, Male(Participants)SelexipagPlaceboTotal
Female457466923
Male117116233
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SelexipagPlaceboTotal
Caucasion / White376375751
Asian125120245
Hispanic5163114
Black131427
Other91019
Region of Enrollment
Region of Enrollment(Participants)SelexipagPlaceboTotal
Western Europe & Australia161160321
Eastern Europe149155304
Asia115113228
North America9598193
Latin America5456110
PAH etiology
PAH etiology(Participants)SelexipagPlaceboTotal
Idiopathic312337649
Heritable131326
Associated with connective tissue disease167167334
Assoc. with corrected (>=12Mo) congenital shunts6050110
Associated with drug or toxin exposure171027
Associated with HIV infection5510
Modified NYHA/WHO Functional class (FC)
Modified NYHA/WHO Functional class (FC)(Participants)SelexipagPlaceboTotal
FC I459
FC II274255529
FC III293314607
FC IV3811
PAH medications at baseline
PAH medications at baseline(Participants)SelexipagPlaceboTotal
None112124236
Endothelin Receptor Agonists (ERA)9476170
Phosphodiesterase type 5 inhibitors (PDE5-I)189185374
ERA and PDE5I in combination179197376
Time since PAH diagnosis
Time since PAH diagnosis(Years)SelexipagPlaceboTotal
Median0.9 (0.0 to 37.3)1.1 (0.0 to 38.9)1.0 (0.0 to 38.9)

1 further baseline measures are reported on the registry.

08

Study locations

182 sites
  • University of South Alabama
    Mobile, Alabama 36617, United States
  • The University of Arizona, Clinical and Translational Science (CATS) Research Center
    Tucson, Arizona 85704, United States
  • University of California San Diego Medical Center (La Jolla)
    La Jolla, California 92037, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • GLVA Healthcare Center
    Los Angeles, California 90073, United States
  • University of California, Davis, UC Davis Medical Center
    Sacramento, California 95817, United States
  • LIU Center for Pulmonary Hypertension
    Torrance, California 90502-2006, United States
  • Lung Health & Sleep Emhancement Center, LLC
    Newark, Delaware 19713, United States
  • Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
    Atlanta, Georgia 30322, United States
  • Georgia Health Sciences University
    Augusta, Georgia 30912-3135, United States
  • Georgia Clinical Research
    Austell, Georgia 30106, United States
  • Clarian North Hospital
    Carmel, Indiana 46032, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • LSU Health Science Center - New Orleans
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital - Pulmonary Critical Care Unit
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital-Pulmonary Critical Care Unit
    Boston, Massachusetts 02114, United States
  • Boston University School of Medicine / Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Beaumont Hospital
    Troy, Michigan 48307, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
    Newark, New Jersey 07112, United States
  • Columbia University Medical Center, Pediatric Cardiology
    New York, New York 10032, United States
  • Montefiore Medical Center, Weiler Division
    The Bronx, New York 10461, United States
  • Duke University Medical Center
    Durham, North Carolina 27710-0001, United States
  • The Lindner Clinical Trial Center
    Cincinnati, Ohio 45219-2906, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43221, United States
  • Oregon Pulmonary Associates, PC
    Portland, Oregon 97225, United States
  • Central Bucks Specialists
    Doylestown, Pennsylvania 18901, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37232-2386, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas-Houston Health Center Department of Pulmonary & Critical Care
    Houston, Texas 77030, United States
  • University of Wisconsin Hospital-Department of Medicine
    Madison, Wisconsin 53792, United States
  • St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Froedtert Hospital - Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
    Buenos Aires, C1119ACN, Argentina
  • Sanatorio Otamendi y Miroli S.A.
    Buenos Aires, C1121ABL, Argentina
  • Hospital Britanico-Pneumology
    Buenos Aires, C1280AEB, Argentina
  • Sanatorio San Jose
    Buenos Aires, C1425DUH, Argentina
  • Instituto De Cardiologia de Corrientes
    Corrientes, W3400AMZ, Argentina
  • Hospital Privado Centro Medico de Cordoba S.A.
    Córdoba, X5016KEH, Argentina
  • St. Vincent's Hospital / Heart and Lung Transplant Unit
    Darlinghurst, New South Wales 2010, Australia
  • Prince Charles Hospital Lung Transplant, Thoracic Department
    Chermside, Queensland 4032, Australia
  • Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology
    Bedford Park, South Australia 5042, Australia
  • St Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • Royal Hobart Hospital, Centre for Clinical Research
    Hobart, TAS 7000, Australia
  • John Hunter Hospital Autoimmune Resource and Research Centre
    New Lambton, 2305, Australia
  • Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine
    Parkville, VIC 3050, Australia
  • Royal Perth Hospital
    Perth, 6000, Australia
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • Medical University of Vienna and AKH Cardiology
    Vienna, A-1090, Austria
  • The Republican Scientific-Practical Center "Cardiology"
    Minsk, 220036, Belarus
  • Minsk City Hospital No. 9
    Minsk, 220116, Belarus
  • Minsk Regional Clinical Hospital of the Red Banner of Labour
    Minsk, 223040, Belarus
  • Ulb Erasme, Cardiology
    Brussels, 1070, Belgium
  • University Hospital Gasthuisberg - Pneumologie
    Leuven, 3000, Belgium
  • University of Alberta Hospital - Children's Centre
    Edmonton, Alberta T6G2C8, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Health Sciences Centre
    Winnipeg, Manitoba R3A 1R8, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • University Health Network
    Toronto, Ontario M5G 2N2, Canada
  • Hopital General Juif (Jewish General Hospital)
    Montreal, Quebec H3T 1E2, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec
    Québec, Quebec G1V 4G5, Canada
  • Instituto Nacional del Torax Teaching Dept
    Santiago, 7500691, Chile
  • Clinica Tabancura- Cardiology Unit
    Santiago, 7650018, Chile
  • Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares
    Santiago, 8330074, Chile
  • Peking Union Medical College Hospital, Rheumatology Department
    Beijing, 100032, China
  • Cardiovascular Institute & Fuwai Hospital-Pulmonary Vascular Center
    Beijing, 100037, China
  • Beijing Shijitan Hospital
    Beijing, 100038, China
  • Guangdong General Hospital, Cardiology Department
    Guangzhou, 510080, China
  • Renji Hospital, Rheumatology Department
    Shanghai, 200001, China
  • Renji Hospital, Cardiology Department
    Shanghai, 200127, China
  • Shanghai Pulmonary Hospital, Department of Pulmonary Circulation
    Shanghai, 200433, China
  • Fundacion Cardio Infantil
    Bogotá, Colombia
  • Fundacion Clinica Shaio
    Bogotá, Colombia
  • Gen Faculty Hosp Prague Cardiology Clin
    Prague, 128 08, Czechia
  • Aarhus University Hospital , Cardiology
    Aarhus, 8200, Denmark
  • Rigshospitalet, Hjertemedicinsk klinik - Cardiology
    Copenhagen, 2100, Denmark
  • Hosp Pradel Lyon - Dpt Pneumology
    Bron, 69677, France
  • Hosp Cote de Nacre - Dpt Pneumology
    Caen, 14033, France
  • Hosp A. Beclere - Dept Pulmo & Resp Intensive Care
    Clamart, 92140, France
  • Hosp Huriez - Dpt Internal Medecine
    Lille, 59037, France
  • Hosp Civil - Dpt Pneumology
    Strasbourg, 67091, France
  • Hosp Larrey - Dpt Pneumology
    Toulouse, 31059, France
  • DRK Kliniken Köpenick
    Berlin, 12559, Germany
  • "Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"
    Cologne, 50924, Germany
  • Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13
    Dresden, 01307, Germany
  • "Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"
    Giessen, 35392, Germany
  • Universität Greifswald / Klinik für Innere Medizin B
    Greifswald, 17487, Germany
  • Medizinische Hochschule Hannover / Klinik für Pneumologie
    Hanover, 30625, Germany
  • Thoraxklinik am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany

Showing the first 100 of 182 sites across 39 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. PubMed 26699168 ↗
  • Benza RL, Chin KM, Gaine S, Galie N, Hoeper MM, Lang IM, McLaughlin VV, Sitbon O, Doad G, Yen J, Tang X, Tapson V. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study. J Heart Lung Transplant. 2024 Dec;43(12):1998-2007. doi: 10.1016/j.healun.2024.08.019. Epub 2024 Aug 31. PubMed 39222737 ↗
  • Galie N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. PubMed 34727317 ↗
  • Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galie N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest. 2021 Jul;160(1):277-286. doi: 10.1016/j.chest.2021.01.066. Epub 2021 Feb 3. PubMed 33545163 ↗
  • Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360. PubMed 30982349 ↗
  • McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galie N. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010. PubMed 29447737 ↗
  • Coghlan JG, Channick R, Chin K, Di Scala L, Galie N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z. PubMed 29307087 ↗
  • Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug 17;50(2):1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug. PubMed 28818881 ↗
  • Krause A, Machacek M, Lott D, Hurst N, Bruderer S, Dingemanse J. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):477-485. doi: 10.1002/psp4.12202. Epub 2017 May 27. PubMed 28556581 ↗
  • Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2014 Feb;15(3):429-36. doi: 10.1517/14656566.2014.876007. Epub 2014 Jan 7. PubMed 24392948 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2009 to primary completion in Apr 2014, 52 months.

Results were first posted in Mar 2016, 1 year 11 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 52 months is close to that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2010
First posted
Apr 19, 2010
StartActual
Dec 1, 2009
Primary completionActual
Apr 1, 2014
CompletionActual
Oct 1, 2014
Results first posted
Mar 1, 2016
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01106014
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 19, 2010
Start date
Dec 1, 2009
Primary completion
Apr 1, 2014
Completion
Oct 1, 2014
Results posted
Mar 1, 2016
Last update
Oct 27, 2025

Study contacts

Aline Frey
study director · Actelion

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion